Appili Therapeutics Inc. (“Appili”), an anti-infective drug development company, announced today that Stephen Nicolle has been appointed to its board of directors. A seasoned executive, Mr. Nicolle has led companies to deliver innovative customer value and returned over $100 million to their investors.
“When it comes to leading venture-backed companies, Mr. Nicolle brings unparalleled business expertise and vision that will be instrumental as we grow and develop our pipeline of anti-infective products,” said Kevin Sullivan, CEO of Appili Therapeutics.
“I am attracted by Appili’s strategic approach of acquiring and developing early stage and late stage products which uniquely address the global demand for new antibiotic treatments to combat bacterial resistance,” said Stephen Nicolle, board director of Appili Therapeutics. “I am honoured to join Appili’s board and look forward to making a contribution to this ambitious and exciting start-up company.”
Mr. Nicolle has 20 years of experience leading companies and growing shareholder value. He is currently president of Cape Bear Advisors where he consults and holds numerous board positions, including vice chair of the start-up accelerator Propel ICT. Mr. Nicolle is the former CEO of leading healthcare technology company, STI Technologies, where he negotiated agreements with top pharmaceutical companies resulting in an increase in revenue of 500 per cent. Before STI Technologies Mr. Nicolle spent 10 years leading venture-backed technology companies, including: CEO of Tatara Systems, CEO of Sigma Systems, COO at March Networks, and president of Nortel’s service provider eBusiness Solutions Group.He is a graduate of Western University with an honours degree in computer science.
Mr. Sullivan makes this announcement as he heads to San Francisco, where the life science industry’s largest investor conference, the JP Morgan Healthcare Conference, is being held.
About Appili Therapeutics Inc.
Appili is dedicated to identifying, acquiring and advancing novel therapeutics for infectious disease. The company has two anti-infective programs, ATI-1501 and ATI-1503, in its pipeline. ATI-1501, a taste-masked treatment for anaerobic infections, including Clostridium difficile, has been granted orphan drug status by the FDA. Appili plans to take ATI-1501 into clinical trials in 2017. Appili’s second product, ATI-1503, is a novel antibiotic with broad potential to treat deadly Gram-negative infections such as Klebsiella pneumoniae. These drug-resistant infections have been identified by the U.S. Center for Disease Control (CDC) as posing the highest threat to human health. For more information visit www.appilitherapeutics.com.
For more information, please contact:
Halifax, Nova Scotia, January 6, 2017